Zwitterionic polymer-coated immunobeads for blood-based cancer diagnostics

Biomaterials

Volumn 35, Issue 1, 2014, Pages 294-303

  Kim, Gahee ^a   Yong, Yeryoung ^a   Kang, Hyun Ju ^a   Park, Kyunghee ^a   Kim, Seung Il ^b   Lee, Myoyong ^a   Huh, Nam ^a  

^a Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Cancer; Circulating biomarker; Immunoaffinity bead; Microvesicle; MiRNA; Zwitterionic monomer

Indexed keywords

CANCER; IMMUNOAFFINITY; MICROVESICLE; MIRNA; ZWITTERIONIC MONOMERS;

ANTIGEN-ANTIBODY REACTIONS; BIOMARKERS; BLOOD; DIAGNOSIS; DISEASES; PLASMAS; PROTEINS;

RNA;

CD83 ANTIGEN; DIAGNOSTIC AGENT; MICRORNA; SAIT BEAD; UNCLASSIFIED DRUG;

ADSORPTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST DISEASE; CANCER CELL; CANCER DIAGNOSIS; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SURFACE PROPERTY; TUMOR DERIVED MICROVESICLE;

CANCER; CIRCULATING BIOMARKER; IMMUNOAFFINITY BEAD; MICROVESICLE; MIRNA; ZWITTERIONIC MONOMER;

ANTIGENS, CD; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULINS; MEMBRANE GLYCOPROTEINS; MICRORNAS; MICROSCOPY, ELECTRON, SCANNING; POLYMERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84887020954     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.101     Document Type: Article

References (32)

1. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 2012, 5(3):492-497.
2. Friend C., Marovitz W., Henie G., Henie W., Tsuei D., Hirschhorn K., et al. Observations on cell lines derived from a patient with Hodgkin's disease. Cancer Res 1978, 38(8):2581-2591.
3. Skog J., Wurdinger T., VanRijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10(12):1470-1476.
4. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Circulating microRNAs: next-generation biomarkers for early lung cancer detection. Clin Lung Cancer 2009, 10:42-46.
5. Logozzi M., DeMilito A., Lugini L., Borghi M., Calabro L., Spada M., et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009, 4(4):e5219.
6. Mitchell P.J., Welton J., Staffurth J., Court J., Mason M.D., Tabil Z., et al. Can urinary exosomes act as treatment response markers in prostate cancer?. JTransl Med 2009, 7:4-16.
7. Li J., Sherman-Baust C.A., Tsai-Turton M., Bristow R.E., Roden R.B., Morin P.J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 2009, 9:244.
8. Iwasaki Y., Ishihara K. Phosphorylcholine-containing polymers for biomedical applications. Anal Bioanal Chem 2005, 381:534-546.
9. Colak S., Tew G.N. Dual-Functional ROMP-Based Betaines: effect of hydrophilicity and backbone structure on nonfouling properties. Langmuir 2012, 28:666-675.
10. Chen S.F., Zheng J., Li L.Y., Jiang S. Strong resistance of phosphorylcholine self-assembled monolayers to protein adsorption: insights into nonfouling properties of zwitterionic materials. JAm Chem Soc 2005, 127(41):14473-14478.
11. Miyagawa S., Soeda J., Takagi S., Miwa S., Ichikawa E., Noike T. Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 2004, 35(11):1392-1396.
12. Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D., Negro A., et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010, 16(1):98-105.
13. Baleeir R.B., Bergami-Santos P.C., Tomiyoshi M.Y., Gross J.L., Haddad F., Pinto C.A., et al. Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?. Cancer Immunol Immunother 2008, 57(2):265-270.
14. Hock B.D., Fernyhough L.J., Gough S.M., Steinkasserer A., Cox A.G., McKenzie J.L. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res 2009, 33(8):1089-1095.
15. Hock B.D., Kato M., McKenzie J.L., Hart D.N. Asoluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol 2001, 13:959-967.
16. Hock B.D., Haring L.F., Steinkasserer A., Taylor K.G., Patton W.N., McKenzie J.L. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res 2004, 28(3):237-241.
17. Chen L, Zhu Y, Zhang G, Gao C, Zhong W, Zhang X. CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2 2011;108(46):18778-83.
18. Holterman D.A., Duncan D.A., Deng T., Smith S.E., Spetzler D.B., Kuslich C.D. AACR 2011.
19. Tauro B.J., Greening D.W., Mathias R.A., Mathivanan S., Ji H., Simpson R.J. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics 2013, 12(3):587-598.
20. Kesimer M., Scull M., Brighton B., DeMaria G., Burns K., O'Neal W., et al. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J 2009, 23(6):1858-1868.
21. Epple L.M., Griffiths S.G., Dechkovskaia A.M., Dusto N.L., White J., Ouellette R.J., et al. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS One 2012, 7(7):e42064.
22. Caby M.P., Lankar D., Vincendeau-Scherrer C., Raposo G., Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005, 17(7):879-887.
23. Kim G., Yoo C.E., Kim M., Kang H.J., Park D., Lee M., et al. Noble polymeric surface conjugated with zwitterionic moieties and antibodies for the isolation of exosomes from human serum. Bioconjug Chem 2012, 23(10):2114-2120.
24. Shiratory S.S., Rubner M.F. pH-Dependent thickness behavior of sequentially adsorbed layers of weak polyelectrolytes. Macromolecules 2000, 33(11):4213-4219.
25. Duffy M.J. Serum tumor markers in breast cancer: are they of clinical value?. Clin Chem 2006, 52(3):345-351.
26. Margolis M.L., Hyzy J.B., Schenken L.L., Schepart B.S. Serum tumor markers in non-small cell lung cancer. A comparative analysis. Cancer 1994, 73(3):605-609.
27. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. NEngl J Med 1987, 317(15):909-916.
28. Rustin G.J.S. Use of CA-125 to assess response to new agents in ovarian cancer trials. JClin Oncol 2003, 21(10):187s-193s.
29. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001, 47(4):624-630.
30. Steward A.M., Nixon D., Zamcheck N., Aisenberg A. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 1974, 33:1246-1252.
31. Anonymous Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. JClin Oncol 1996, 14(10):2843-2877.
32. Koga K., Matsumoto K., Akiyoshi T., Kubo M., Yamanaka N., Tasaki A., et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res 2005, 25(6):3703-3707.